High-Dose Convalescent Plasma for Treatment of Severe COVID-19

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: De Santis, Gil C., Oliveira, Luciana Correa, Garibaldi, Pedro M.M., Almado, Carlos E.L., Croda, Julio, Arcanjo, Ghislaine G.A., Oliveira, Érika A.F., Tonacio, Adriana C., Langhi, Dante M., Bordin, José O., Gilio, Renato N., Palma, Leonardo C., Santos, Elaine V., Haddad, Simone K., Prado, Benedito P.A., Pontelli, Marjorie Cornejo, Gomes, Rogério, Miranda, Carlos H., Martins, Maria Auxiliadora, Covas, Dimas T., Arruda, Eurico, Fonseca, Benedito A.L., Calado, Rodrigo T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888205/
https://www.ncbi.nlm.nih.gov/pubmed/35081022
http://dx.doi.org/10.3201/eid2803.212299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888205/
https://www.ncbi.nlm.nih.gov/pubmed/35081022
http://dx.doi.org/10.3201/eid2803.212299

Ejemplares similares